When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Bladder cancer - Wikipedia

   en.wikipedia.org/wiki/Bladder_cancer

   Five-year survival rates range from 5% to 96% depending ... Deaths: Around 200,000 each year: Bladder cancer is the abnormal growth of cells on the ... (CIS). [9] CIS ...

3. List of cancer mortality rates in the United States - Wikipedia

   en.wikipedia.org/wiki/List_of_cancer_mortality...

   Cancer mortality rates are determined by the relationship of a population's health and lifestyle with their healthcare system. In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [ 1 ]

4. Cancer survival rates - Wikipedia

   en.wikipedia.org/wiki/Cancer_survival_rates

   In the United States there has been an increase in the 5-year relative survival rate between people diagnosed with cancer in 1975-1977 (48.9%) and people diagnosed with cancer in 2007-2013 (69.2%); these figures coincide with a 20% decrease in cancer mortality from 1950 to 2014. [8]

5. 5 cancer types where screenings save the most lives - AOL

   www.aol.com/news/5-cancer-types-where-screenings...

   Over a 45-years span — between 1975 and 2020 — improvements in cancer screenings and prevention strategies have reduced deaths from five common cancers more than any advances in treatments ...

6. Carcinoma in situ - Wikipedia

   en.wikipedia.org/wiki/Carcinoma_in_situ

   For this reason, CIS will usually not form a tumor. Rather, the lesion is flat (in the skin, cervix, etc.) or follows the existing architecture of the organ (in the breast, lung, etc.). Exceptions include CIS of the colon (polyps), the bladder (preinvasive papillary cancer), or the breast (ductal carcinoma in situ or lobular carcinoma in situ).

7. Gilead's Trodelvy fails bladder cancer trial, modestly ... - AOL

   www.aol.com/news/gileads-trodelvy-extends-lung...

   (Reuters) -Gilead Sciences' Trodelvy failed to improve survival for patients with advanced bladder cancer and only modestly extended the lives of previously treated patients with late-stage lung ...